Glenmark Pharma’s US Division Introduces Lacosamide Oral Solution for Seizure Treatment

Glenmark Pharmaceuticals has launched the Lacosamide oral solution, 10mg/ml, in the US market on December 16, 2024. This oral solution is used in the treatment of seizures, including partial onset seizures and primary generalized tonic-clonic seizures. The company is positioning this launch as a significant milestone in its efforts to offer affordable and quality alternatives to existing treatments for patients in need.

Bioequivalence with Vimpat Oral Solution

Glenmark's Lacosamide oral solution is bioequivalent and therapeutically equivalent to Vimpat Oral Solution (10mg/ml) produced by UCB, Inc. Vimpat is a well-established drug in the market, and Glenmark’s new offering is designed to provide the same therapeutic benefits, ensuring that patients receive a comparable, reliable treatment option. The bioequivalence of Glenmark’s formulation assures patients and healthcare providers that they will experience similar clinical effects with the new oral solution.

Market Insights and Financial Impact

According to IQVIA's yearly sales data for October 2024, Vimpat Oral Solution 10mg/ml achieved annual sales of approximately $57 million in the US. By introducing its own version of this medication, Glenmark Pharma aims to capture a portion of this market, offering an affordable alternative that could potentially reduce healthcare costs for patients.

Statement from Glenmark's Leadership

Marc Kikuchi, President and Business Head for North America at Glenmark Pharma, expressed excitement about the product launch. He emphasized the company's commitment to providing high-quality and affordable therapeutic solutions to patients. This launch marks a step forward in Glenmark’s goal to expand its product portfolio in North America and offer viable alternatives to branded medications for a wider patient population.

Glenmark’s Progress in Cancer Research

In addition to the launch of the Lacosamide oral solution, Glenmark Pharma also shared promising results from a Phase 1 clinical study of its Trispecific TREAT Antibody (ISB 2001) in treating Multiple Myeloma. The early clinical data revealed a high overall response rate of 75% across all tested doses, with promising outcomes in terms of durable responses and favorable safety profiles. The study involved 20 patients, and the results suggest that ISB 2001 may prove to be a competitive option in the treatment of Multiple Myeloma, potentially comparable to existing bispecific therapies.

Glenmark Pharma’s Share Price and Performance

On December 16, 2024, Glenmark Pharma’s shares saw a slight increase of 1.23%, reaching ₹1,536.80 per share. The stock has demonstrated impressive growth, with a year-to-date gain of 79.61%. This positive performance reflects the company’s consistent efforts to expand its market presence and innovate in the pharmaceutical space, particularly in the fields of oncology and neurology.

Conclusion

Glenmark Pharmaceuticals’ launch of the Lacosamide oral solution in the US marks a significant milestone in the company’s efforts to expand its presence in the neurology sector. By offering a bioequivalent and therapeutically equivalent alternative to Vimpat, Glenmark not only provides a cost-effective treatment option for patients but also strengthens its commitment to delivering quality healthcare solutions. The launch comes at a time when the demand for seizure treatments is substantial, with Vimpat generating significant market sales. With ongoing innovation, including promising clinical trials in other areas such as multiple myeloma, Glenmark is well-positioned to continue its growth and contribute meaningfully to the global pharmaceutical landscape. This strategic move reflects the company's long-term vision to deliver affordable and effective medicines while strengthening its position in the highly competitive US market.